NeuroPace cut full year 2026 revenue guidance to $91M to $92M on November 12, down from $99.5M to $101.5M. Third quarter revenue was $23.1M, down 1.1 percent from $23.4M a year earlier. RNS System revenue was $22.9M, up 1.4 percent.

CEO Joel Becker tied the shortfall to several of the largest accounts, isolated account level problems and changes to the field organization that caused more disruption than the company expected. He said fourth quarter scheduled cases have started to recover. NeuroPace trimmed non-GAAP operating expense guidance to $85M to $86M from $90M to $92M, raised gross margin guidance to 83.0 to 83.5 percent, and widened its adjusted EBITDA loss range to $8.5M to $9.5M.

Two regulatory items are moving. After an October submission issue request meeting, NeuroPace is preparing an amendment to its PMA supplement for idiopathic generalized epilepsy, expected around year end. A separate supplement covering telehealth programming of the RNS System is in a 180-day review. A sales reorganization showing up inside a guidance cut of roughly $9M is the detail to watch, because implant volume at this scale rides on a small number of account relationships.